NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.
Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role...
Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a...
